We looked the pharma industry right in the eye and said: Now, it’s our turn. Millions of women suffer from Hypoactive (low) Sexual Desire Disorder (HSDD), and they deserve to be heard. We opened bedroom doors and welcomed a long overdue conversation about women and sex. When our product launched, there were 26 different treatments for male sexual dysfunction available and none for women. So we made it our obligation to break through with the first. We changed the game for women and haven’t stopped making noise since.
We were acquired by Valeant for $1B in 2015. Two years later, in an unprecedented move, our CEO Cindy Eckert and her shareholders re-acquired Sprout. We’ve since relaunched our product at a price that strives to ensure more women have access.